EP-1 and EP-2: AKR1C3-Activated Antitumor Drug Conjugate Efficacy and Toxicity Data

A 315-byte dataset from figshare, last updated in May 2026, describes the preclinical evaluation of two novel AKR1C3-activated Exatecan drug conjugates, EP-1 and EP-2. The data, authored by Ningfang Kang, includes results from in vitro cytotoxicity assays, cellular and zebrafish imaging for drug release tracking, and in vivo mouse model efficacy and toxicity studies. The findings nominate EP-2 as a candidate for selective tumor therapy with reduced systemic toxicity.

Use Cases

• Compare in vitro cytotoxicity (IC50 values) of novel conjugates EP-1 and EP-2 against the parent drug Exatecan based on the description.
• Analyze the relationship between AKR1C3 enzyme expression and targeted drug activation based on the described selective mechanism.
• Evaluate the reduction of systemic toxicity using maximum tolerated dose (MTD) data from mouse models mentioned in the description.
• Study real-time drug release dynamics using the fluorescence-quenched module described for cellular and zebrafish imaging.

Strengths

• Includes specific in vitro cytotoxicity metrics (IC50: 7.7 ± 0.2 nM for EP-1, 4.6 ± 0.4 nM for EP-2).
• Reports a concrete in vivo maximum tolerated dose (MTD > 60 mg/kg for EP-2) compared to Exatecan.
• Data validates drug efficacy in overcoming sorafenib resistance, as mentioned in the description.

Limitations

• The dataset is extremely small (315 bytes), indicating very limited scope or summary-level data.
• Row count and column-level documentation are unknown; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains summarized results from preclinical laboratory experiments described in the associated research.

Freshness

Last updated 2026-05-02 13:32:52; freshness should be verified.